Monday, October 25

Daily News Day 2 coverage includes expert commentary on studies presented during Sunday's Clinical Trials and Innovation Session, a preview of today's Keynote and this afternoon's Plenary Session and much more! 

Digital Daily October 25, 2021 Access the Digital Daily from day 2 at the ASTRO Annual Meeting.
SABR-5 trial SABR-5 trial confirms low risk of high grade toxicity for treatment of oligometastases with SABR
CONCORDE Trial Phase II/III randomized trial CONCORDE (PRODIGE-26) fails to find benefit to dose-escalated definitive chemoradiotherapy in esophageal cancer
PROs from NRG/RTOG 0815 Short-term androgen deprivation therapy causes a significant but self-limited decrement in patient-reported outcomes
Stage 3 NSCLC Combined Checkpoint Blockade Inhibition and Concurrent Chemoradiation Therapy in Stage 3 Non-small Cell Lung Cancer: A Bridge Too Far?
ADT with RT for Prostate Should androgen deprivation therapy be used with radiation therapy in prostate cancer treatment?

American Society for Radiation Oncology
251 18th Street South, 8th Floor
Arlington, VA 22202
Telephone: 703-502-1550


Connect With Us: